Clinical Trial

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

Name: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — clinical trial record (NCT06613360)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Protocol Amendment History 1 change

notable Trial sites expanded: 17 -> 20 locations 2026-06-06

Trial Details

NCT Number	NCT06613360
Lead Sponsor	Cullinan Therapeutics Inc.
Conditions	SLE, SLE (Systemic Lupus)
Enrollment	24 participants
Start Date	2025-01-21
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-05